Provenge for prostate cancer – pro
Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The recommended course of therapy for Provenge (sipuleucel-T) is three complete doses, given at approximately 2-week intervals. NCCN recommends it for non-symptomatic disease of when life expectancy is greater that 6 months; for other cases it recommends docetaxel.
On April 29, 2010, the FDA approved Provenge as follows: PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
http://www.bcbs.com/blueresources/tec/vols/24/special-report-vaccines-for.html
Provenge (sipuleucel-T) [package insert]. Seattle, WA: Dendreon Corporation; April 2010.
Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T Immunotherapy for Castration-resistant Prostate Cancer. N Engl J Med. 2010;363:411-422.
nccn.org.prostate, PROS-9 2014